IO Biotech

IO Biotech Total Assets

Delisted·Sep 22, 2026

The Total Assets of IO Biotech (IOBT) as of Nov 20, 2026 is 67.70 M USD. In the previous year, Total Assets was 150.72 M USD — a change of -55.08% (lower).

Total Assets

67.70 MUSD

YoY

-55.08%

Last updated:

Total Assets of IO Biotech is 2024 67.70 M USD. Total Assets of IO Biotech was 2023 150.72 M USD. It decreases by -55.08% lower compared to the previous year.

The IO Biotech Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2019
9.42 M USD
Jan 1, 2020
5.65 M USD
Jan 1, 2021
222.29 M USD
Jan 1, 2022
151.81 M USD
Jan 1, 2023
150.72 M USD
Jan 1, 2024
67.70 M USD
The IO Biotech Total Assets history
YEARTotal AssetsYoY
67.70 MUSD-55.08%
150.72 MUSD-0.72%
151.81 MUSD-31.71%
222.29 MUSD+3,832.21%
5.65 MUSD-40.01%
9.42 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IO Biotech Stock analysis

What does IO Biotech do? IO Biotech, Inc. develops immune modulating cancer therapies using its T-win technology platform. The Company focuses on product candidates that target immunosuppressive proteins like IDO and PD-L1, aiming to disrupt tumor-induced immunosuppression. Its lead candidate, IO102-IO103, is designed to address multiple pathways regulated by these proteins. The firm's pipeline includes therapies leveraging T-win to target the tumor microenvironment (TME). IO Biotech's revenue model is based on the development and potential commercialization of its product candidates. The company generates income through partnerships with pharmaceutical firms for the development and licensing of its therapies. These partnerships are formed with entities interested in advancing immune modulating cancer treatments. The target market includes pharmaceutical companies seeking innovative cancer therapy solutions. The firm's technology platform, T-win, is central to its business strategy. By targeting key immunosuppressive proteins such as IDO and PD-L1, IO Biotech addresses a critical need in cancer treatment. Its lead product candidate, IO102-IO103, is positioned to disrupt multiple immunosuppressive pathways, offering a novel approach to cancer therapy. IO Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IO Biotech stock

Total Assets of IO Biotech is 67.70 M USD in 2024.

Total Assets of IO Biotech changed from 150.72 M USD to 67.70 M USD, representing a -55.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets IO Biotech since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's IO Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — IO Biotech

All Key Metrics — IO Biotech